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year. Tumor size is the strongest predictor of survival. Surgery is the treatment of choice in early disease stage. In local advanced
stages, radiotherapy associated or not to chemotherapyhas beenused.Wepresent a case treatedwith external beamradiotherapy
and interstitial brachytherapy.
Material and methods. A gynecological examination performed to an 81 year old woman with vaginal bleeding and local pain
revealed a tumor mass attached to the anterior and lateral walls of the vagina and coming out the introitus. MRI and PET-
CT revealed a 6.4 cm tumor mass in the upper third of the vagina embracing the urethral septum without metastases. Biopsy
conﬁrmed malignant primary vaginal melanoma. She underwent external beam radiotherapy to the pelvis, receiving a total dose
of 46Gy, followed by interstitial brachytherapy with high dose rate (HDR) up to a 60Gy total dose.
Results. Six months later, a reduction of 3 cm in tumor size was observed on physical examination, conﬁrmed by MRI/PET-TC; 12
months clinical and repeated imaging demonstrated persistent disease in the anterior wall of the vagina on urethral meatus.
No symptom of vaginal bleeding was reported, but local pain was not controlled and patient was referred to Pain Unit. No acute
urinary or rectal toxicity were observed. The patient died 14 months later.
Conclusions. Local excision is the treatment of choice in early disease but most patients are diagnosed at advanced stage. A
combination of EBRT and interstitial brachytherapy is a reasonable treatment, but tumor size is a limitation to local control this
vagina melanoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.238
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Purpose and objective. Elevation of the SCC in early cervical cancer is associated with nodal and lymphovascular inﬁltration, and is
regarded as a marker for the need of treatment- chemo and/or radiotherapy (RT)- and poor prognosis. In this study we analyzed
SCC value as a prognostic factor before chemo-RT treatment and after completion.
Materials and methods. We followed a cohort of 236 patients from 1999 to 2011, under a weekly scheme with IV cisplatin (40mg/m2)
and concomitant RT. FIGO stage distribution was as follows: 7 (IB1), 27 (IB2), 2 (IIA), 73 (IIB), 1 (IIIA), 109 (IIIB), 17 (IVA). The SCC at
diagnosis was elevated above the cutoff point (1.5 or 2.5ng/ml) in 160 (67.8%) patients and was considered normal in 76 (32.2%).
Themeanvalues of SCC for different FIGO stageswere: IB1=1.04, IB2=5.36, IIA=0.55, IIB = 13.86, IIIA=31.80, IIIB = 20.03, IVA=34.75
(p<0.0001). The mean value amongst patients with elevated SCC, was 22.5 (r: 1.7–235, p25=4.8, p50=11.4, p75=22.4). In order to
assess SCC values at diagnosis (SCCD), we grouped patients according to their initial values: SCCD0=normal SCC, SCCD1=high
SCC -up to the value of percentile 50- (<11.4) and SCCD2=SCC≥11.4. At the end of the chemo-RT, clinical response was assessed
by physical examination (PE) and the value of SCC: PE was normal in 188 patients reﬂecting complete clinical response (CR); a
partial response (PR) over 50% was observed in 47 patients, and 1 patient remained with stable disease (SD); SCC was normal in
214 patients (SCCT0) and remained elevated in 20 (SCCT1). SCC was not performed in only 2 patients. When grouping patients
according to their combination of SCC and clinical response at the end of treatment, we obtained the following prognosis groups
(PG): PG0 (CR and normal SCC, n=173 patients), PG1 (CR and high SCC, n=14), PG2 (PR and normal SCC, n=41) and PG3 (SD and
high SCC, n=6).
Results. The mean follow-up-time was 55 months. An overall 5 year (SG5) survival using actuarial method (SG5) was found at
72.3%, with 67 deaths occurring in the following period. No statistical differences in SG5 were found between patients with
normal or elevated SCC at diagnosis, but the grouped analysis-according to SCCD- showed differences among SCCD0, SCCD1
and SCCD2 groups with values 76.2%, 86% and 57.5% respectively (p=0.0006). SG5 between SCCT1 and SCCT0 patients was 70.3%
and 25% respectively (p<0.0001), and for those with CR and PR, SG5 was 76.2% and 58.3% (p<0.0001). Finally, the SG5 in patients
PG0, PG1, PG2, PG3 was: 79.3%, 47.1%, 64.8%, and 16% respectively (p<0.0001).
Conclusions. SG5 showed to be similar amongst patients with normal and elevated SCC at diagnosis; however, an SCC value above
11.4ng/ml, showed to have worse results.
http://dx.doi.org/10.1016/j.rpor.2013.03.239
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Introduction. The treatment of locally advanced cervical carcinoma (LACC) is concomitant chemoradiation followed by brachyther-
apy or surgery as the answer reached. The objective is know our results in terms of overall survival (OS), disease-free
survival (DFS), relapse-free survival (RFS), metastasis-free survival (MFS) and toxicity (RTOG) of patients with LACC treated with
radiochemotherapy.
Material and methods. Between 1998 and June-2012, 107 patients, mean age 55±13 (25–83), were analyzed retrospectively. Distri-
bution by stages (FIGO): Ib2=10.3%, IIa = 17.8%, IIb = 31.8%, IIIa = 3.7% IIIb = 29.9% and IVA=6.6%. Histologically, 88% epidermoid
